Whittier Trust Co. of Nevada Inc. Boosts Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Whittier Trust Co. of Nevada Inc. grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 157.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,180 shares of the medical equipment provider's stock after acquiring an additional 14,172 shares during the quarter. Whittier Trust Co. of Nevada Inc.'s holdings in Intuitive Surgical were worth $11,387,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Creekmur Asset Management LLC boosted its position in shares of Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 42 shares during the last quarter. Ridgewood Investments LLC purchased a new position in shares of Intuitive Surgical during the second quarter valued at approximately $26,000. Delos Wealth Advisors LLC boosted its holdings in Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 57 shares during the last quarter. Godsey & Gibb Inc. grew its position in Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 35 shares during the period. Finally, LRI Investments LLC purchased a new stake in Intuitive Surgical during the 1st quarter valued at $30,000. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Stock Performance

Shares of ISRG traded down $2.29 during midday trading on Monday, hitting $518.86. 1,308,869 shares of the company traded hands, compared to its average volume of 1,477,745. The stock has a market cap of $184.04 billion, a price-to-earnings ratio of 93.66, a PEG ratio of 5.40 and a beta of 1.39. The firm has a 50 day moving average of $484.91 and a 200-day moving average of $439.55. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $523.34.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same period in the prior year, the company earned $1.18 earnings per share. The firm's revenue was up 14.5% on a year-over-year basis. Sell-side analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on ISRG shares. The Goldman Sachs Group set a $604.00 price objective on Intuitive Surgical in a report on Friday. Barclays raised their price objective on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an "overweight" rating in a report on Thursday, July 18th. Citigroup upped their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a "buy" rating in a report on Thursday, August 22nd. Royal Bank of Canada increased their price target on shares of Intuitive Surgical from $525.00 to $555.00 and gave the stock an "outperform" rating in a research report on Friday. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $513.74.

Insider Activity

In related news, insider Mark Brosius sold 2,115 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the sale, the insider now owns 295 shares in the company, valued at approximately $145,113.45. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the transaction, the insider now owns 295 shares in the company, valued at approximately $145,113.45. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Amy L. Ladd sold 450 shares of the company's stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $490.28, for a total value of $220,626.00. Following the sale, the director now owns 821 shares in the company, valued at approximately $402,519.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.